In December 2022, the Government of Ontario announced that the current Ontario Health Insurance Plan (OHIP) will no longer cover specific biologic medications, only biosimilar medications, beginning on December 29th 2023. 1 The class of biologic medications are defined as being derived from a living source, such as cells or living organisms. This is compared to conventional small molecule drugs, which are created chemically. Common examples of biologics include growth hormones and insulin. One specific subset of biologic medications, also called biotherapeutics or biopharmaceuticals, are vastly complex molecules created to treat a number of autoimmune diseases including cancer, diabetes, blood disorders, rheumatoid/psoriatic arthritis, Crohn’s disease and ulcerative colitis, among others. 2,3 From hereon, “biologics” and “biologic medications” will refer to the latter examples. Due to their high cost, biologic medications are commonly being removed from provincial public formularies. These changes are forced upon patients and leave them with a reduced number of treatment modalities. The following position paper advocates for a patient-focused transition to lower-cost biologic medications, balancing patient-autonomy, and responsible healthcare spending.